Biostatistician with more than 5 years of experience working in the pharmaceutical industry. Primary therapeutic areas of interest are CVRM (cardiovascular, renal and metabolism). Experience in contributing to the development of the statistical strategy, overseeing the technical activities related to design, delivery and interpretation, as well as participating in high level internal governance committees and regulatory submissions of a project, and representing Biometrics in cross-functional collaborations. Teaching experience from Le Mans University, American University of Armenia and Yerevan State University. The main taught courses are Statistics and Data Science with R. Research interests are in the field of Statistics of Stochastic Processes.
PhD in Mathematical Statistics, 2016
Le Mans University, France
MSc in Theory of Probability and Mathematical Statistics, 2012
Yerevan State University, Armenia
BSc in Mathematics, 2010
Yerevan State University, Armenia
Biostatistician working in Phase 3 cardiovascular outcome trials:
Responsibilities include:
Producing Scientific Documents in Armenian.
EasyStat App is an R
based FREE web application. This platform can help you to independently conduct research data analyses.
The win odds is a distribution-free method of comparing locations of distributions of two independent random variables. Introduced as a method for analyzing hierarchical composite endpoints, it is well suited to be used in the analysis of ordinal scale endpoints in COVID-19 clinical trials. For a single outcome, we provide power and sample size calculation formulas for the win odds test. We also provide an implementation of the win odds analysis method for a single ordinal outcome in a commonly used statistical software to make the win odds analysis fully reproducible.
DARE-19 was a randomised, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (ie, hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease). Patients were randomly assigned 1:1 to dapagliflozin (10 mg daily orally) or matched placebo for 30 days.
Dapagliflozin reduced the risk of total (first and repeat) HF hospitalizations and cardiovascular death. Time-to-first event analysis underestimated the benefit of dapagliflozin in HF and reduced ejection fraction.
DARE-19 will evaluate whether dapagliflozin can prevent COVID-19-related complications and all-cause mortality, or improve clinical recovery, and assess the safety profile of dapagliflozin in this patient population. Currently, DARE-19 is the first large randomized controlled trial investigating use of sodium-glucose cotransporter 2 inhibitors in patients with COVID-19.
The win ratio is a general method of comparing locations of distributions of two independent, ordinal random variables, and it can be estimated without distributional assumptions. In this paper we provide a unified theory of win ratio estimation in the presence of stratification and adjustment by a numeric variable.
This work is devoted to the questions of the statistics of stochastic processes. Particularly, the first chapter is devoted to a non-parametric estimation problem for an inhomogeneous Poisson process. The second chapter is dedicated to a problem of estimation of the solution of a Backward Stochastic Differential Equation (BSDE).